Supreme Court And Patents: What’s Not Happening
Executive Summary
High court denies petition by Mylan to limit patent litigation venue and petition by Merck KGAA to address whether “on sale” bar to obtaining patent applies to non-public sales; Zarxio case to go to conference Friday.
You may also be interested in...
Does Sale Of Confidential Invention Prevent Its Patenting? US Supreme Court Will Review
Helsinn v. Teva challenges whether inventor's sale of an invention to a third party that must in turn keep the invention secret makes it unpatentable; America Invents Act amended "on-sale" bar provision.
Biosimilar Launch Notification: Solicitor General Backs Pre-FDA Approval Notice
Government urges Supreme Court to take up Sandoz’s Zarxio petition challenging Federal Circuit’s interpretation of the biosimilars statue; says it should also review Amgen’s challenge of ruling on patent dance.
Mylan Wants Supreme Court To Limit Patent Litigation Venue
Federal Circuit decision permits brand-name drug makers to file infringement suits against generic manufacturers in whatever jurisdiction they wish.